Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies

被引：4
作者：
Sureda, Anna [1 ]
Dreger, Peter [2 ,3 ]
Bishop, Michael R. [4 ]
Kroger, Nicolaus [5 ]
Porter, David L. [6 ,7 ]
机构：
[1] Hosp Barcelona, Inst Catala Oncol, Hematol Dept, Barcelona, Spain
[2] Heidelberg Univ, Dept Med 5, Heidelberg, Germany
[3] European Soc Blood & Marrow Transplantat EBMT, Leiden, Netherlands
[4] Univ Chicago, Hematopoiet Cellular Therapy Program, Sect Hematol Oncol, Chicago, IL 60637 USA
[5] Univ Med Ctr, Dept Stem Cell Transplantat, Hamburg, Germany
[6] Univ Penn, Div Hematol Oncol, Blood & Marrow Transplant Program, Philadelphia, PA 19104 USA
[7] Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
BONE MARROW TRANSPLANTATION | 2019年 / 54卷 / 01期
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; DIAGNOSED MULTIPLE-MYELOMA; PROGRAMMED DEATH-1 BLOCKADE; 2ND INTERNATIONAL WORKSHOP; HIGH-DOSE CHEMOTHERAPY; BRENTUXIMAB VEDOTIN; CONSOLIDATION THERAPY; ALLOGENEIC TRANSPLANTATION; CONDITIONING REGIMENS; HODGKINS LYMPHOMA;
D O I：
10.1038/s41409-018-0214-5
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
Relapse is now the major cause of treatment failure after allogeneic HSCT (alloHSCT). Many novel strategies to address this critical issue are now being developed and tested. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg, Germany in November 2016, international experts presented and discussed recent developments in the field. Some approaches may be applicable to a wide range of patients after transplant, whereas some may be very disease-specific. We present a report from the session dedicated to issues related to prevention and treatment of relapse of lymphoid malignancies after alloHSCT. This session included detailed reviews as well as forward-looking commentaries that focused on Hodgkin lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma, diffuse large cell and follicular lymphoma, and multiple myeloma.
引用
收藏
页码：17 / 25
页数：9
相关论文
共 83 条
  • [21] Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
    Dreger, Peter
    Doehner, Hartmut
    Ritgen, Matthias
    Boettcher, Sebastian
    Busch, Raymonde
    Dietrich, Sascha
    Bunjes, Donald
    Cohen, Sandra
    Schubert, Joerg
    Hegenbart, Ute
    Beelen, Dietrich
    Zeis, Matthias
    Stadler, Michael
    Hasenkamp, Justin
    Uharek, Lutz
    Scheid, Christof
    Humpe, Andreas
    Zenz, Thorsten
    Winkler, Dirk
    Hallek, Michael
    Kneba, Michael
    Schmitz, Norbert
    Stilgenbauer, Stephan
    [J]. BLOOD, 2010, 116 (14) : 2438 - 2447
  • [22] The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
    Dreyling, Martin
    Ferrero, Simone
    [J]. HAEMATOLOGICA, 2016, 101 (02) : 104 - 114
  • [23] Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality
    Fenske, Timothy S.
    Zhang, Mei-Jie
    Carreras, Jeanette
    Ayala, Ernesto
    Burns, Linda J.
    Cashen, Amanda
    Costa, Luciano J.
    Freytes, Cesar O.
    Gale, Robert P.
    Hamadani, Mehdi
    Holmberg, Leona A.
    Inwards, David J.
    Lazarus, Hillard M.
    Maziarz, Richard T.
    Munker, Reinhold
    Perales, Miguel-Angel
    Rizzieri, David A.
    Schouten, Harry C.
    Smith, Sonali M.
    Waller, Edmund K.
    Wirk, Baldeep M.
    Laport, Ginna G.
    Maloney, David G.
    Montoto, Silvia
    Hari, Parameswaran N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04) : 273 - +
  • [24] Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience
    Gayoso, J.
    Balsalobre, P.
    Pascual, M. J.
    Castilla-Llorente, C.
    Lopez-Corral, L.
    Kwon, M.
    Serrano, D.
    Pinana, J. L.
    Herrera, P.
    Ferra, C.
    Pascual, C.
    Heras, I.
    Montesinos, P.
    Zabalza, A.
    Bento, L.
    Figuera, A.
    Buno, I.
    Diez-Martin, J. L.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 (10) : 1307 - 1312
  • [25] Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
    Gisselbrecht, Christian
    Schmitz, Norbert
    Mounier, Nicolas
    Gill, Devinder Singh
    Linch, David C.
    Trneny, Marek
    Bosly, Andre
    Milpied, Noel J.
    Radford, John
    Ketterer, Nicolas
    Shpilberg, Ofer
    Duehrsen, Ulrich
    Hagberg, Hans
    Ma, David D.
    Viardot, Andreas
    Lowenthal, Ray
    Briere, Josette
    Salles, Gilles
    Moskowitz, Craig H.
    Glass, Bertram
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (36) : 4462 - 4469
  • [26] Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
    Gopal, Ajay K.
    Chen, Robert
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Chi, Xuedong
    Sievers, Eric L.
    Younes, Anas
    [J]. BLOOD, 2015, 125 (08) : 1236 - 1243
  • [27] Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
    Gopal, Ajay K.
    Ramchandren, Radhakrishnan
    O'Connor, Owen A.
    Berryman, Robert B.
    Advani, Ranjana H.
    Chen, Robert
    Smith, Scott E.
    Cooper, Maureen
    Rothe, Achim
    Matous, Jeffrey V.
    Grove, Laurie E.
    Zain, Jasmine
    [J]. BLOOD, 2012, 120 (03) : 560 - 568
  • [28] Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse
    Hahn, M.
    Boettcher, S.
    Dietrich, S.
    Hegenbart, U.
    Rieger, M.
    Stadtherr, P.
    Bondong, A.
    Schulz, R.
    Ritgen, M.
    Schmitt, T.
    Tran, T. H.
    Goerner, M.
    Herth, I.
    Luft, T.
    Schoenland, S.
    Witzens-Harig, M.
    Zenz, T.
    Kneba, M.
    Ho, A. D.
    Dreger, P.
    [J]. BONE MARROW TRANSPLANTATION, 2015, 50 (10) : 1279 - 1285
  • [29] Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
    Herbaux, Charles
    Gauthier, Jordan
    Brice, Pauline
    Drumez, Elodie
    Ysebaert, Loic
    Doyen, Helene
    Fornecker, Luc
    Bouabdallah, Krimo
    Manson, Guillaume
    Ghesquieres, Herve
    Tabrizi, Reza
    Hermet, Eric
    Lazarovici, Julien
    Thiebaut-Bertrand, Anne
    Chauchet, Adrien
    Demarquette, Helene
    Boyle, Eileen
    Houot, Roch
    Yakoub-Agha, Ibrahim
    Morschhauser, Franck
    [J]. BLOOD, 2017, 129 (18) : 2471 - 2478
  • [30] Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
    Hermine, Olivier
    Hoster, Eva
    Walewski, Jan
    Bosly, Andre
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Szymczyk, Michal
    Bouabdallah, Reda
    Kneba, Michael
    Hallek, Michael
    Salles, Gilles
    Feugier, Pierre
    Ribrag, Vincent
    Birkmann, Josef
    Forstpointner, Roswitha
    Haioun, Corinne
    Haenel, Mathias
    Casasnovas, Rene Olivier
    Finke, Juergen
    Peter, Norma
    Bouabdallah, Kamal
    Sebban, Catherine
    Fischer, Thomas
    Duehrsen, Ulrich
    Metzner, Bernd
    Maschmeyer, Georg
    Kanz, Lothar
    Schmidt, Christian
    Delarue, Richard
    Brousse, Nicole
    Klapper, Wolfram
    Macintyre, Elizabeth
    Delfau-Larue, Marie-Helene
    Pott, Christiane
    Hiddemann, Wolfgang
    Unterhalt, Michael
    Dreyling, Martin
    [J]. LANCET, 2016, 388 (10044) : 565 - 575
123456789